Joseph(Joe) Basile Purchases 5,000 Shares of Neuren Pharmaceuticals Limited (ASX:NEU) Stock

Neuren Pharmaceuticals Limited (ASX:NEUGet Free Report) insider Joseph(Joe) Basile acquired 5,000 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was acquired at an average cost of A$11.99 ($7.74) per share, with a total value of A$59,950.00 ($38,677.42).

Neuren Pharmaceuticals Price Performance

About Neuren Pharmaceuticals

(Get Free Report)

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome.

Further Reading

Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with's FREE daily email newsletter.